QDEL

$19.12

Post-MarketAs of Mar 17, 8:00 PM UTC

QuidelOrtho Corporation provides diagnostic testing solutions.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$19.12
Potential Upside
5%
Whystock Fair Value$20.08
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.30B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-46.15%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.77

Recent News

Zacks
Mar 13, 2026

Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report?

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Mar 13, 2026

QuidelOrtho (QDEL) Valuation Check After Prolonged Share Price Weakness And Earnings Challenges

QuidelOrtho (QDEL) has drawn attention after a prolonged share price slide, with returns over the past month and past 3 months both negative. This has prompted investors to reassess the diagnostics group. See our latest analysis for QuidelOrtho. The recent slide fits a longer pattern, with a 30 day share price return of negative 38.65% and a 1 year total shareholder return of negative 49.66%, suggesting a shift in momentum as investors reassess growth prospects and risk. If this pullback has...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 9, 2026

Rice Hall James Buys QuidelOrtho Stock

QuidelOrtho develops diagnostic technologies for healthcare providers worldwide, spanning labs, clinics, and retail settings.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
StockStory
Mar 9, 2026

3 Unprofitable Stocks That Concern Us

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 6, 2026

PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.